Last Price$68.62.5%
Market Cap$2,075.9M
LTM Long-Term Investments
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
5/10
76.6% overvalued
Belite Bio, Inc Long-Term Investments
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
| Long-Term Investments | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for BLTE
and see if it's the right time to invest.
Belite Bio, Inc (BLTE) Long-Term Investments comparison analysis
General
LTM Long-Term Investments
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Belite Bio, IncBLTE
$0.0
N/A
N/A
N/A
Median Peer Set
$329.7M
0.0%
0.0%
0.0%
Royalty Pharma plcRPRX
$16.4B
1,518.5%
3.9%
7.4%
Vertex Pharmaceuticals IncorporatedVRTX
$5,107.9M
96.7%
N/A
N/A
United Therapeutics CorporationUTHR
$1,475.3M
(22.8%)
(3.7%)
14.0%
BioNTech SEBNTX
$1,298.5M
0.0%
289.0%
N/A
BioMarin Pharmaceutical Inc.BMRN
$521.2M
(14.7%)
0.9%
4.8%
BeiGene, Ltd.BGNE
$138.2M
54.8%
16.5%
37.2%
Alnylam Pharmaceuticals, Inc.ALNY
$0.0
(100.0%)
(100.0%)
(100.0%)
Summit Therapeutics Inc.SMMT
$0.0
N/A
N/A
N/A
Regeneron Pharmaceuticals, Inc.REGN
($1,136.0M)
N/A
N/A
N/A
argenx SEARGX
N/A
N/A
N/A
N/A
BLTE key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.2 | 0.4 |
% margin | (0.0) 0.0% | (0.0) 0.0% | (0.2) 0.0% | (0.4) 0.0% |
| Operating Expenses | 5.7 | 9.8 | 12.8 | 31.7 |
| Research & Development Expenses (R&D) | 3.7 | 7.4 | 8.9 | 24.8 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 4.0 | 6.8 |
% margin | (5.7) 0.0% | (9.8) 0.0% | (12.8) 0.0% | (31.7) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.1 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (5.8) | (9.7) | (12.6) | (31.6) |
% effective tax rate | 0.0 (0.0%) | 0.1 (1.3%) | (0.2) 1.4% | 0.0 (0.0%) |
% margin | (5.8) 0.0% | (9.8) 0.0% | (12.5) 0.0% | (31.6) 0.0% |
| EPS | (0.24) | (0.41) | (0.62) | (1.19) |
| Diluted EPS | (0.24) | (0.41) | (0.62) | (1.19) |
% margin | (5.7) 0.0% | (9.6) 0.0% | (12.4) 0.0% | (31.5) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Belite Bio, Inc's Long-Term Investments?
As of today, Belite Bio, Inc's last 12-month Long-Term Investments is $0.0, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Belite Bio, Inc's Long-Term Investments growth rate?
Over the last year, Belite Bio, Inc's Long-Term Investments growth was N/A. The average annual Long-Term Investments growth rates for Belite Bio, Inc have been N/A over the past three years, N/A over the past five years.